{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:06Z","timestamp":1788865986552,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregnant and lactating women are generally excluded from clinical trials during vaccine development. While the safety, inmunogenicity, efficacy, and effectiveness of the Abdala vaccine against COVID-19 have been demonstrated in the general population, there is a lack of specific information regarding its benefits for pregnant women. Consequently, this study was undertaken to evaluate the safety of the Abdala vaccine in pregnant women and their newborns, as well as to assess the maternal immune response elicited by the vaccination and its capacity for passive immunity transfer to the newborn.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A simple cohort observational multicenter study was conducted across five maternity hospital in Havana City, Cuba. A hybrid approach was employed, integrating both retrospective and prospective data collection methods. The study analyzed all events occurring from the first dose of the Abdala vaccine during pregnancy, delivery, and the postpartum period, as well as those related to the fetus-\/neonate. To provide contextual data from our settings as a reference for descriptive analyses, statistical information concerning some pregnancy-related and fetal-neonatal events from the same five maternity hospitals in the year 2020 was utilized (historical data). Immunogenicity analyses were conducted in a subgroup of participants from a single maternity hospital, measuring antibodies against the receptor-binding domain of SARS-CoV-2 (Anti-RBD IgG antibodies) and neutralizing antibodies (Nab) against two SARS-CoV-2 strains (D614G and Omicron B.1.1.529) were measured in both maternal and umbilical cord sera. Additionally, anti-IgA antibodies were evaluated in a colostrum samples. Antibody transfer across the placenta and breast milk was also analyzed. Various comparisons were made regarding gestational age at birth, vaccination trimester, timing from vaccination to delivery, and receipt of a booster dose, among other analyses. A formal sample size estimate was not made. Pregnant women who attended the aforementioned hospitals and met the established criteria were included in the study cohort. Descriptive statistics were utilized to characterize the study population. The Wilcoxon sum rank test was used for most immunological evaluations, while logistic regression analyses estimated the effects of different variables. The correlation between anti-RBD IgG titers in maternal and umbilical cord sera was assessed using Pearson's correlation coefficient. All statistical tests were performed at a significance level of\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study was conducted in five Cuban hospitals from December 2021 to June 2022, involving a total of 940 pregnant women women who received the Abdala vaccine during their pregnancy. The common adverse events reported within the 72\u00a0h post-vaccination with the Abdala vaccine were consistent with previous findings using this vaccine in clinical trials and widespread vaccination campaigns in the general population, predominantly presenting as pain at the injection site (4.9%), somnolence (2.6%), and headache (2.3%). All reported events were of mild intensity. In terms of maternal morbidity, the predominant event noted was SARS-CoV-2 infection, with 83 cases (8.83%), primarily categorized as asymptomatic cases or exhibiting mild symptomatic disease. Overall, IgA titers were detected in 202 colostrum samples, with GMT of 1,227 (95% CI 986; 1,527). High anti-RBD IgG titers were found in 189 maternal and 231 umbilical cord blood samples, with GMT of 1,392.15 (95% CI 1,174; 1,651) and 1,923 (95% CI 1,625; 2,275) respectively. The placental transfer ratio (PTR) of anti-RBD IgG titers had a median of 1.54 (IQR 1.48), indicating effective transfer. The PTR of NAb exceeded 1 for both D614G and Omicron (B.1.1.529), being significantly higher in full-term newborns compared to premature newborns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ESPIRTA study provides valuable information concerning the application of the Abdala vaccine in specific populations, such as pregnant women, which was not available prior to this study. The safety evaluation of the Abdala vaccine during pregnancy, delivery and the puerperium, as well as in fetus-newborn, revealed no safety signals, as indicated by this cohort study. Elevated anti-RBD IgG titers were detected, in both in maternal serum and cord samples, indicating a positive correlation between them. Moreover, an efficient transfer of IgG antibodies across the placenta was demonstrated. The high anti-IgA titers found in the colostrum may provide an additional advantage regarding the passive transfer of antibodies from mother to newborn through breastfeeding. Furthermore, neutralizing antibodies against two SARS-CoV-2 strains, D614 G and the more recent Omicron B.1.1.529 variant, were identified. Further research is recommended to assess the long-term safety and efficacy of the Abdala vaccine for pregnant women and their newborns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-026-09488-1","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:14:24Z","timestamp":1782278064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of safety and immunogenicity of a protein subunit COVID-19 vaccine (ABDALA) in pregnant women: a single-cohort, multicenter, observational ESPIRTA study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jorge Antonio Aguilar","family":"Estrada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idania Baladr\u00f3n","family":"Castrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Campa","family":"Legr\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Arsenio D\u00edaz","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonieta Costafreda","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudith Cambrero","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuleisi","family":"de la Caridad Preval Calsado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Enr\u00edquez","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osmany Franco","family":"Argote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoisi Verrier","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaima Le\u00f3n","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Sarduy","family":"N\u00e1poles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenia Almenares","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto Rodr\u00edguez","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando Selgas","family":"Lizano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas E. S\u00e1nchez","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marel Alonso","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda Lemos","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudisay Reyes","family":"Pelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Padr\u00f3n","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miladys","family":"Limonta-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ayala-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz Alvarez-Lajonchere Ponce","family":"de Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena L. Muzio-","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Espirta Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"9488_CR1","doi-asserted-by":"publisher","first-page":"m3320","DOI":"10.1136\/bmj.m3320","volume":"370","author":"J Allotey","year":"2020","unstructured":"Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. https:\/\/doi.org\/10.1136\/bmj.m3320.","journal-title":"BMJ"},{"issue":"44","key":"9488_CR2","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.15585\/mmwr.mm6944e3","volume":"69","author":"LD Zambrano","year":"2020","unstructured":"Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm6944e3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"9488_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamapediatrics.2021.1050","volume":"175","author":"J Villar","year":"2021","unstructured":"Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817\u201326. https:\/\/doi.org\/10.1001\/jamapediatrics.2021.1050.","journal-title":"JAMA Pediatr"},{"key":"9488_CR4","unstructured":"Centers for Disease Control and Prevention. Information about COVID-19 vaccines for People who are pregnant or breastfeedin. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/pregnancy.html. Accessed 8 Mar 2021."},{"key":"9488_CR5","unstructured":"FIGO. Vacunaci\u00f3n contra la COVID-19 para mujeres embarazadas y lactantes\/FIGO 2021. https:\/\/www.figo.org\/es\/vacunacion-contra-la-covid-19-para-mujeres-embarazadas-y-lactantes"},{"key":"9488_CR6","unstructured":"Considerations for Obstetric-Gynecologic Care. Accessed June 29, 2023. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care"},{"issue":"3","key":"9488_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/AOG.0000000000004290","volume":"137","author":"SA Rasmussen","year":"2021","unstructured":"Rasmussen SA, Kelley CF, Horton JP, Jamieson DJ. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know. Obstet Gynecol. 2021;137(3):408\u201314. https:\/\/doi.org\/10.1097\/AOG.0000000000004290.","journal-title":"Obstet Gynecol"},{"key":"9488_CR8","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccines While Pregnant or Breastfeeding. Updated March 3, 2022. https:\/\/www.cdc.gov\/covid\/vaccines\/pregnant-or-breastfeeding.html. Accessed 28 Jun 2024."},{"issue":"72","key":"9488_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbt.2022.08.002","volume":"25","author":"M Limonta-Fern\u00e1ndez","year":"2022","unstructured":"Limonta-Fern\u00e1ndez M, Chinea-Santiago G, Mart\u00edn-Dunn AM, et al. An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen. N Biotechnol. 2022;25(72):11\u201321. https:\/\/doi.org\/10.1016\/j.nbt.2022.08.002.","journal-title":"N Biotechnol"},{"key":"9488_CR10","doi-asserted-by":"publisher","first-page":"101383","DOI":"10.1016\/j.eclinm.2022.101383","volume":"46","author":"F Hern\u00e1ndez-Bernal","year":"2022","unstructured":"Hern\u00e1ndez-Bernal F, Ricardo-Cobas MC, Martin-Bauta Y, et al. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1\u20132 clinical trial (ABDALA Study). eClinicalMedicine. 2022;46:101383. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101383.","journal-title":"eClinicalMedicine."},{"key":"9488_CR11","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.lana2023.100497","volume":"21","author":"F Hern\u00e1ndez-Bernal","year":"2023","unstructured":"Hern\u00e1ndez-Bernal F, Ricardo-Cobas MC, Martin-Bauta Y, et al. A phase 3, randomized, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARSCoV- 2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study). Lancet Reg Health Am. 2023;21:100497. https:\/\/doi.org\/10.1016\/j.lana2023.100497.","journal-title":"Lancet Reg Health Am"},{"key":"9488_CR12","doi-asserted-by":"publisher","first-page":"100366","DOI":"10.1016\/j.lana.2022.100366","volume":"16","author":"PI M\u00e1s-Bermejo","year":"2022","unstructured":"M\u00e1s-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodr\u00edguez K, et al. Cuban Abdala vaccine: effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; a cohort study. Lancet Reg Health Am. 2022;16:100366. https:\/\/doi.org\/10.1016\/j.lana.2022.100366.","journal-title":"Lancet Reg Health Am."},{"key":"9488_CR13","doi-asserted-by":"publisher","first-page":"102160","DOI":"10.1016\/j.eclinm.2023.102160","volume":"63","author":"Z Cinza-Est\u00e9vez","year":"2023","unstructured":"Cinza-Est\u00e9vez Z, Resik-Aguirre S, Figueroa-Baile NL, et al. Immunogenicity and Safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3 to 18 years old: a double-blinded, multicentr1e, randomised, phase 1\/2 clinical trial (ISMAELILLO study). eClinicalMedicine. 2023;63:102160. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102160.","journal-title":"eClinicalMedicine."},{"key":"9488_CR14","doi-asserted-by":"publisher","first-page":"126223","DOI":"10.1016\/j.vaccine.2023.126223","volume":"42","author":"F Hern\u00e1ndez-Bernal","year":"2024","unstructured":"Hern\u00e1ndez-Bernal F, Noa-Romero E, Quintana-Guerra J, et al. Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 3 trial (ME\u00d1IQUE). Vaccine. 2024;42:126223. https:\/\/doi.org\/10.1016\/j.vaccine.2023.126223.","journal-title":"Vaccine"},{"key":"9488_CR15","unstructured":"Global manual on surveillance of adverse events following immunization.2016 update. Available at https:\/\/www.who.int\/publications\/i\/item\/9789241507769"},{"key":"9488_CR16","unstructured":"CECMED UMELISA SARS-COV-2 IGG (Cuban sanitary Registry D2107\u201311). Available at https:\/\/www.cecmed.cu\/covid-19\/aprobaciones\/umelisa-sars-cov-2-igg"},{"issue":"10","key":"9488_CR17","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/jmv.25986","volume":"92","author":"A Manenti","year":"2020","unstructured":"Manenti A, Maggetti M, Casa E, et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J Med Virol. 2020;92(10):2096\u2013104. https:\/\/doi.org\/10.1002\/jmv.25986.","journal-title":"J Med Virol"},{"issue":"2","key":"9488_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajog.2021.03.035","volume":"225","author":"LB Mithal","year":"2021","unstructured":"Mithal LB, Otero S, Shanes ED, et al. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol. 2021;225(2):192\u20134. https:\/\/doi.org\/10.1016\/j.ajog.2021.03.035.","journal-title":"Am J Obstet Gynecol."},{"key":"9488_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fmicb.2022.927306","volume":"927306","author":"M Heidary","year":"2022","unstructured":"Heidary M, Kaviar VH, Shirani M, et al. A comprehensive review of the protein subunit vaccines against COVID-19. Front Microbiol. 2022;927306:13. https:\/\/doi.org\/10.3389\/fmicb.2022.927306.","journal-title":"Front Microbiol"},{"issue":"4","key":"9488_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5339\/qmj.2022.52","volume":"2022","author":"F Minisha","year":"2022","unstructured":"Minisha F, Farrell T, Abuyaqoub S, et al. Maternal risk factors of COVID-19-affected pregnancies: A comparative analysis of symptomatic and asymptomatic COVID-19 from the Q-PRECIOUS registry. Qatar Medical Journal. 2022;2022(4):52. https:\/\/doi.org\/10.5339\/qmj.2022.52.","journal-title":"Qatar Medical Journal"},{"issue":"24","key":"9488_CR21","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","volume":"384","author":"TT Shimabukuro","year":"2021","unstructured":"Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2104983.","journal-title":"N Engl J Med"},{"issue":"10","key":"9488_CR22","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cmi.2023.06.015","volume":"29","author":"G Favre","year":"2023","unstructured":"Favre G, Maisonneuve E, Pomar L, et al. Risk of congenital malformation after first trimester mRNA COVID-19 vaccine exposure in pregnancy: the COVI-PREG prospective cohort. Clin Microbiol Infect. 2023;29(10):1306\u201312. https:\/\/doi.org\/10.1016\/j.cmi.2023.06.015.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"9488_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/AOG.0000000000005632","volume":"144","author":"A Denoble","year":"2024","unstructured":"Denoble A, Vazquez-Benitez G, Sheth S, et al. Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstet Gynecol. 2024;144(2):215\u201322. https:\/\/doi.org\/10.1097\/AOG.0000000000005632.","journal-title":"Obstet Gynecol"},{"key":"9488_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2393-4-17","volume":"4","author":"VM Allen","year":"2004","unstructured":"Allen VM, Joseph K, Murphy KE, et al. The effect of hypertensive disorders in pregnancy on small for gestational age and stillbirth: a population-based study. BMC Pregnancy Childbirth. 2004;4:17. https:\/\/doi.org\/10.1186\/1471-2393-4-17.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"25","key":"9488_CR25","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1016\/j.vaccine.2023.03.038","volume":"41","author":"A Ciapponi","year":"2023","unstructured":"Ciapponi A, Berrueta M, Parker EPK, et al. Safety of COVID-19 vaccines during pregnancy: a systematic review and meta-analysis. Vaccine. 2023;41(25):3688\u2013700. https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.038.","journal-title":"Vaccine."},{"issue":"16","key":"9488_CR26","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/diagnostics14161775","volume":"14","author":"A Gerede","year":"2024","unstructured":"Gerede A, Daskalakis G, Mikos T, Chatzakis C, Vavoulidis E, Eleftheriades M, et al. Safety of COVID-19 Vaccination in pregnancy: a systematic review. Diagnostics. 2024;14(16):1775. https:\/\/doi.org\/10.3390\/diagnostics14161775.","journal-title":"Diagnostics"},{"issue":"23","key":"9488_CR27","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.2021.7563","volume":"325","author":"AY Collier","year":"2021","unstructured":"Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. 2021;325(23):2370\u201380. https:\/\/doi.org\/10.1001\/jama.2021.7563.","journal-title":"JAMA"},{"issue":"3","key":"9488_CR28","doi-asserted-by":"publisher","first-page":"303.e1","DOI":"10.1016\/j.ajog.2021.03.023","volume":"225","author":"KJ Gray","year":"2021","unstructured":"Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225(3):303.e1-303.e17. https:\/\/doi.org\/10.1016\/j.ajog.2021.03.023.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"9488_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/AOG.0000000000004438","volume":"138","author":"M Prabhu","year":"2021","unstructured":"Prabhu M, Murphy EA, Sukhu AC, et al. Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet Gynecol. 2021;138(2):278\u201380. https:\/\/doi.org\/10.1097\/AOG.0000000000004438.","journal-title":"Obstet Gynecol"},{"key":"9488_CR30","doi-asserted-by":"publisher","first-page":"127476","DOI":"10.1016\/j.vaccine.2025.127476","volume":"62","author":"W Sheridan","year":"2025","unstructured":"Sheridan W, Rincon M, Keen K, et al. SARS-CoV-2 breakthrough infection during pregnancy preferentially elicits IgG4 response and enhanced placental-transfer. Vaccine. 2025;62:127476. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127476.","journal-title":"Vaccine"},{"issue":"2","key":"9488_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1530\/ror.0.0040081","volume":"4","author":"F Saji","year":"1999","unstructured":"Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Revi Reprod. 1999;4(2):81\u20139. https:\/\/doi.org\/10.1530\/ror.0.0040081.","journal-title":"Revi Reprod."},{"issue":"5","key":"9488_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","volume":"36","author":"A Malek","year":"1996","unstructured":"Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulinsduring human pregnancy. Am J Reprod Immunol. 1996;36(5):248\u201355. https:\/\/doi.org\/10.1111\/j.1600-0897.1996.tb00172.x.","journal-title":"Am J Reprod Immunol"},{"key":"9488_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41541-023-00698-8","volume":"8","author":"G Marchand","year":"2023","unstructured":"Marchand G, Masoud AT, Grover S, et al. Maternal and neonatal outcomes of COVID-19 vaccination during pregnancy, a systematic review and meta-analysis. NPJ Vaccines. 2023;8:103. https:\/\/doi.org\/10.1038\/s41541-023-00698-8.","journal-title":"NPJ Vaccines."},{"issue":"3","key":"9488_CR34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cell.2020.12.027","volume":"184","author":"C Atyeo","year":"2021","unstructured":"Atyeo C, Pullen KM, Bordt EA, et al. Compromised SARS-CoV-2-specific placental antibody transfer. Cell. 2021;184(3):628-642.e10. https:\/\/doi.org\/10.1016\/j.cell.2020.12.027.","journal-title":"Cell"},{"issue":"36","key":"9488_CR35","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1016\/j.vaccine.2023.06.032","volume":"41","author":"F Munoz","year":"2023","unstructured":"Munoz F, Posavad C, Richardson B, et al. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. Vaccine. 2023;41(36):5296\u2013303. https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.032.","journal-title":"Vaccine"},{"issue":"10","key":"9488_CR36","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1093\/cid\/ciab266","volume":"73","author":"A Rottenstreich","year":"2021","unstructured":"Rottenstreich A, Zarbiv G, Oiknine-Djian E, et al. Efficient maternofetal transplacental transfer of anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies after antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination. Clin Infect Dis. 2021;73(10):1909\u201312. https:\/\/doi.org\/10.1093\/cid\/ciab266.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"9488_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.31080\/ASMI.2021.04.0926","volume":"4","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R. Role of colostrum in immune-protection and disease prevention in neonates and their post natal life. Acta Sci Microbiol. 2021;4(10):11\u20137.","journal-title":"Acta Sci Microbiol"},{"issue":"4","key":"9488_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.imj.2022.11.001","volume":"1","author":"M P\u00e9rez-Bernal","year":"2022","unstructured":"P\u00e9rez-Bernal M, Hern\u00e1ndez C, Ibargoll\u00edn R, et al. SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala. Infectious Med. 2022;1(4):253\u201361. https:\/\/doi.org\/10.1016\/j.imj.2022.11.001.","journal-title":"Infectious Med"},{"issue":"4","key":"9488_CR39","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.jcvp.2022.100104","volume":"2","author":"MG Guzm\u00e1n","year":"2022","unstructured":"Guzm\u00e1n MG, P\u00e9rez L, Tejero Y, et al. Emergence and evolution of SARS-CoV-2 genetic variants during the Cuban epidemic. J Clin Virol Plus. 2022;2(4):100104. https:\/\/doi.org\/10.1016\/j.jcvp.2022.100104.","journal-title":"J Clin Virol Plus"},{"issue":"3\u20134","key":"9488_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.37757\/MR2022.V24.N3-4.6","volume":"24","author":"L P\u00e9rez-Santos","year":"2022","unstructured":"P\u00e9rez-Santos L, Kouri-Cardella V, Tejero-Suarez Y, et al. Epidemiological characterization of patients in the first eight weeks following detection of SARSCoV-2 B.1.1.529 (omicron) variant in Cuba. MEDICC Rev. 2022;24(3\u20134):18\u201323.","journal-title":"MEDICC Rev"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-026-09488-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-09488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-09488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:28Z","timestamp":1788865408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-026-09488-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9488"],"URL":"https:\/\/doi.org\/10.1186\/s12884-026-09488-1","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Research Committee at each of the participant\u2019s medical institutions: \u201cRam\u00f3n Gonz\u00e1lez Coro\u201d Maternal Hospital, \u201cEusebio Hernandez\u201d Maternal Hospital, \u201cAngel Arturo Aball\u00ed\u201d Maternal Hospital, \u201cHijas de Galicia\u201d Maternal Hospital and \u201cAmerica Arias\u201d Maternal Hospital. The study protocol was in accordance to the Declaration of Helsinki (Fortaleza, 2013). Each participant was assigned a unique identification code, and all data were managed in accordance with the confidentiality standards required for biomedical research. Informed consent was obtained from all participants to safeguard their rights, safety, and well-being.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"998"}}